Safety of Primed Repetitive Transcranial Magnetic Stimulation and Modified Constraint-Induced Movement Therapy in a Randomized Controlled Trial in Pediatric Hemiparesis
To investigate the safety of combining a 6-Hz primed low-frequency repetitive transcranial magnetic stimulation (rTMS) intervention in the contralesional hemisphere with a modified constraint-induced movement therapy (mCIMT) program in children with congenital hemiparesis. Phase 1 randomized, double...
Saved in:
Published in | Archives of physical medicine and rehabilitation Vol. 96; no. 4; pp. S104 - S113 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.04.2015
|
Subjects | |
Online Access | Get full text |
ISSN | 0003-9993 1532-821X 1532-821X |
DOI | 10.1016/j.apmr.2014.09.012 |
Cover
Summary: | To investigate the safety of combining a 6-Hz primed low-frequency repetitive transcranial magnetic stimulation (rTMS) intervention in the contralesional hemisphere with a modified constraint-induced movement therapy (mCIMT) program in children with congenital hemiparesis.
Phase 1 randomized, double-blinded, placebo-controlled pretest/posttest trial.
University academic facility and pediatric specialty hospital.
Subjects (N=19; age range, 8–17y) with congenital hemiparesis caused by ischemic stroke or periventricular leukomalacia. No subject withdrew because of adverse events. All subjects included completed the study.
Subjects were randomized to 1 of 2 groups: either real rTMS plus mCIMT (n=10) or sham rTMS plus mCIMT (n=9).
Adverse events, physician assessment, ipsilateral hand function, stereognosis, cognitive function, subject report of symptoms assessment, and subject questionnaire.
No major adverse events occurred. Minor adverse events were found in both groups. The most common events were headaches (real: 50%, sham: 89%; P=.14) and cast irritation (real: 30%, sham: 44%; P=.65). No differences between groups in secondary cognitive and unaffected hand motor measures were found.
Primed rTMS can be used safely with mCIMT in congenital hemiparesis. We provide new information on the use of rTMS in combination with mCIMT in children. These findings could be useful in research and future clinical applications in advancing function in congenital hemiparesis. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
ISSN: | 0003-9993 1532-821X 1532-821X |
DOI: | 10.1016/j.apmr.2014.09.012 |